Du är här

2014-04-16

Swedish Orphan Biovitrum AB (publ): Sobi publishes Annual Report 2013

Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report
for 2013, themed "Pioneer in Rare Diseases", on the company's website,
www.sobi.com.

The Annual Report summarises 2013, which was an eventful year for Sobi with
several key milestones, and encompasses the company's approach to keeping the
patient journey - from diagnosis and treatment, to on-going disease
management and long-term outcomes - at the centre of how it prioritises its
capabilities and investments. By creating and maintaining a dialogue with key
stakeholders (patients organisations, physicians, governments and payers),
Sobi seeks to ensure that treatments are delivered in a sustainable way. Sobi
refers to this approach as Patient and Customer Centric Commercialisation.

Sobi's Annual Report also includes interviews with key industry stakeholders
as well as patients, giving their perspective on the development of the
pharmaceutical industry and how it is to live with a rare disease,
respectively.

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late stage
biological development projects within Haemophilia and Neonatology. We also
market a portfolio of specialty and rare disease products for partner
companies. Sobi is a pioneer in biotechnology with world-class capabilities
in protein biochemistry and biologics manufacturing. In 2013, Sobi had total
revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO:
SOBI) is listed on NASDAQ OMX Stockholm. More information is available
atwww.sobi.com.

For more information please contact

--------------------------------------------------------------------
|Media relations Investor relations |
|Oskar Bosson Jörgen Winroth |
|Head of Communications Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |
--------------------------------------------------------------------
Pdf version of press release
http://hugin.info/134557/R/1777618/606859.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1777618

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.